SCHEMBL5226093

SCHEMBL5226093

CCOC(=O)CN(Cc1ccc(OCc2ccccc2)cc1)S(=O)(=O)N1CCc2ccccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
LTA4H P09960 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TSPO P30536 1/20 0.42
GRIN1 Q05586 1/20 0.42
GRIN2B Q13224 1/20 0.42
ALOX5 P09917 2/20 0.41
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
LMNA P02545 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
MAPT P10636 2/20 0.41
NR1H4 Q96RI1 1/20 0.41
NOTUM Q6P988 1/20 0.41
ALDH1A1 P00352 2/20 0.41
TP53 P04637 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5223394 0.95 L3MBTL1 (0.41) L3MBTL1LTA4HSMN1; SMN2TSPOALOX5
SCHEMBL5229661 0.91 L3MBTL1 (0.44) MEN1KMT2AL3MBTL1GRIN1GRIN2B
SCHEMBL5228007 0.89 MEN1 (0.47) MEN1KMT2ASMN1; SMN2LMNAMAPT
SCHEMBL5229675 0.86 POLB (0.42) MEN1KMT2AL3MBTL1SMN1; SMN2GRIN1
SCHEMBL5432331 0.85 FFAR1 (0.51) LMNAMAPTTP53
SCHEMBL5225633 0.84 MEN1 (0.45) MEN1KMT2AL3MBTL1SMN1; SMN2LMNA
SCHEMBL5226874 0.83 MAPT (0.45) MEN1KMT2AL3MBTL1SMN1; SMN2LMNA
SCHEMBL5441640 0.82 MAPT (0.48) SMN1; SMN2LMNAMAPTTP53HTT
SCHEMBL5263899 0.81 FFAR1 (0.49) LMNAMAPTTP53
SCHEMBL5229603 0.81 PPARA (0.50) SMN1; SMN2LMNAMAPTALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254882-A1 Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same CRYSTAL GENOMICS, INC. (KR) 2007-11-01 US disclosed
EP-1778654-A1 SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME Crystalgenomics, Inc. (KR) 2007-05-02 EP disclosed
WO-2006006832-A1 SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME CRYSTALGENOMICS, INC. (KR) 2006-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254882-A1 Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same SULT2A1, SPTLC2, SGMS2 MEN1 4183/4885KMT2A 879/4885L3MBTL1 4766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.